Biotech: Page 6

  • Jay Hartenbach, COO, president, Diakanos Oncology
    Image attribution tooltip
    Permission granted by Diakanos
    Image attribution tooltip
    Q&A

    How non-traditional investors fuel up-and-coming biotechs when VC funding dries up

    Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.

    By • March 18, 2025
  • radioactive syringe
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

    Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

    By Kelly Bilodeau • March 17, 2025
  • cancer R&D Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Oncology R&D

    Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

    By PharmaVoice staff
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Q&A

    Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

    The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

    By Amy Baxter • March 17, 2025
  • The dome of the U.S. Capitol Building as seen at dawn.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

    Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

    By Amy Baxter • March 12, 2025
  • brain design with neuro points scattered
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep

    Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

    By Amy Baxter • March 11, 2025
  • Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    What’s driving pharma’s layoffs in 2025

    Familiar foes in the industry have claimed a slew of jobs in recent months.

    By • March 10, 2025
  • M&A handshake
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The time is ripe for pharma M&A. Why are drugmakers holding out?

    The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.

    By • March 6, 2025
  • Large letters spelling Amgen are seen by a wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    With patent losses on the horizon, Amgen refocuses its business strategy

    The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

    By Alexandra Pecci • March 5, 2025
  • Toby Ferguson, chief medical officer, Voyager Therapeutics
    Image attribution tooltip
    Permission granted by Voyager Therapeutics
    Image attribution tooltip

    New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

    Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.

    By • March 4, 2025
  • Ben Taylor, CFO, Recursion Pharmaceuticals
    Image attribution tooltip
    Permission granted by Recursion
    Image attribution tooltip
    Q&A

    AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

    Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.

    By • Feb. 27, 2025
  • Cancer vaccine
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Cancer vaccines have stumbled, but the approach is gaining new steam

    The number of candidates in development has nearly doubled over the past 15 years.

    By Kelly Bilodeau • Feb. 26, 2025
  • hands pills
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Its CEO died. The company scrapped a promising program. Now, for their 2nd act.

    Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.

    By Alexandra Pecci • Feb. 25, 2025
  • Capitol building, DC
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

    Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

    By • Feb. 25, 2025
  • Travis Coy, CFO, Immunocore
    Image attribution tooltip
    Permission granted by Immunocore
    Image attribution tooltip
    Q&A // First 90 Days

    Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

    Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.

    By • Feb. 20, 2025
  • crispr cardio
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Biotech Spotlight

    CRISPR’s cardio catch-all drives a biotech’s broad potential

    Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.

    By Kelly Bilodeau • Feb. 18, 2025
  • Split heart
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split

    The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.

    By • Feb. 13, 2025
  • 3D render using close-up of heart model covered with white, red, yellow pills
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    In the crowded cardio space, it’s David vs. Goliath for small biotechs

    What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

    By Alexandra Pecci • Feb. 11, 2025
  • a tech works in a pharma lab
    Image attribution tooltip
    Permission granted by Fractyl Health
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments

    Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.

    By Amy Baxter • Feb. 10, 2025
  • dollar sign syringe
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D

    With assets under a knife and pipelines under a microscope, R&D programs are being overhauled to be more efficient and cost effective.

    By Alexandra Pecci • Feb. 5, 2025
  • bird flu avian influenza migration
    Image attribution tooltip
    David McNew via Getty Images
    Image attribution tooltip

    Drugmakers prep for bird flu outbreak, despite continued low risk

    While the virus hasn’t made a sustained leap into humans, vaccines and treatments are coming through the pipes if it does.

    By Kelly Bilodeau • Feb. 3, 2025
  • petri dish seeds
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Year in Preview

    Pharma’s forecast for 2025: Sowing seeds of a rebound

    Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation. 

    By • Jan. 31, 2025
  • The Vertex Pharmaceuticals building in daylight on the Boston Seaport.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?

    Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.

    By Amy Baxter • Updated Feb. 4, 2025
  • Jason Hersh, CEO, co-founder, managing partner, Klein Hersh
    Image attribution tooltip
    Permission granted by Klein Hersh
    Image attribution tooltip

    Executive hiring changes reflect a broader biotech comeback

    Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.

    By Alexandra Pecci • Jan. 29, 2025
  • natural killer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Natural killer cells, a rising alternative to CAR-T cell therapy

    These innate immune cells may provide a safer, lower-cost option in cancer and autoimmune diseases.

    By Kelly Bilodeau • Jan. 27, 2025
  • dna helix
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Gene therapies have been uneven for DMD — but these companies hope to turn the tide

    Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.

    By • Jan. 24, 2025